Btc Capital Management Increased Pfizer (PFE) Holding; Novelion Therapeutics (NVLN) Shorts Up By 4.87%

July 17, 2017 - By Stephen Andrade

Novelion Therapeutics Incorporated (NASDAQ:NVLN) had an increase of 4.87% in short interest. NVLN’s SI was 675,800 shares in July as released by FINRA. Its up 4.87% from 644,400 shares previously. With 58,900 avg volume, 12 days are for Novelion Therapeutics Incorporated (NASDAQ:NVLN)’s short sellers to cover NVLN’s short positions. It closed at $9.27 lastly. It is down 31.51% since July 17, 2016 and is uptrending. It has outperformed by 14.81% the S&P500.

Btc Capital Management Inc increased Pfizer Inc (PFE) stake by 10.05% reported in 2016Q4 SEC filing. Btc Capital Management Inc acquired 11,794 shares as Pfizer Inc (PFE)’s stock declined 3.45%. The Btc Capital Management Inc holds 129,127 shares with $4.19 million value, up from 117,333 last quarter. Pfizer Inc now has $199.98B valuation. It closed at $33.43 lastly. It is down 2.76% since July 17, 2016 and is downtrending. It has underperformed by 19.46% the S&P500.

Since February 27, 2017, it had 0 insider purchases, and 5 insider sales for $5.16 million activity. The insider Dolsten Mikael sold $2.02M. 20,000 shares valued at $693,200 were sold by LANKLER DOUGLAS M on Thursday, March 2. 36,000 shares valued at $1.23 million were sold by HILL CHARLES H on Thursday, March 9. On Friday, March 10 the insider JOHNSON RADY A sold $153,855.

Among 20 analysts covering Pfizer (NYSE:PFE), 7 have Buy rating, 1 Sell and 12 Hold. Therefore 35% are positive. Pfizer had 48 analyst reports since July 29, 2015 according to SRatingsIntel. Barclays Capital initiated the stock with “Equal-Weight” rating in Tuesday, December 1 report. The stock of Pfizer Inc. (NYSE:PFE) has “Buy” rating given on Monday, June 20 by Jefferies. The stock of Pfizer Inc. (NYSE:PFE) earned “Hold” rating by Jefferies on Thursday, October 13. The stock of Pfizer Inc. (NYSE:PFE) earned “Neutral” rating by SunTrust on Wednesday, November 25. Berenberg initiated it with “Hold” rating and $38 target in Thursday, May 12 report. The stock has “Overweight” rating by Piper Jaffray on Friday, August 28. The firm has “Buy” rating given on Thursday, July 14 by Jefferies. The company was maintained on Friday, March 24 by Societe Generale. As per Tuesday, November 29, the company rating was upgraded by Barclays Capital. The stock of Pfizer Inc. (NYSE:PFE) has “Overweight” rating given on Friday, August 28 by Piper Jaffray.

Investors sentiment decreased to 1.13 in 2016 Q4. Its down 0.05, from 1.18 in 2016Q3. It fall, as 60 investors sold PFE shares while 672 reduced holdings. 115 funds opened positions while 711 raised stakes. 4.12 billion shares or 1.11% more from 4.08 billion shares in 2016Q3 were reported. Bender Robert & Associate owns 0.36% invested in Pfizer Inc. (NYSE:PFE) for 15,757 shares. Lockheed Martin Inv reported 29,050 shares stake. Lloyds Grp Inc Inc Plc holds 0.12% of its portfolio in Pfizer Inc. (NYSE:PFE) for 444 shares. Allsquare Wealth Management Lc, New York-based fund reported 10,402 shares. Hugh Johnson Limited Liability Company stated it has 0.34% in Pfizer Inc. (NYSE:PFE). Payden & Rygel holds 1.63% in Pfizer Inc. (NYSE:PFE) or 542,590 shares. Colony Group Inc Limited Liability stated it has 7,026 shares. Suntrust Banks accumulated 0.76% or 3.90 million shares. 2.54 million are owned by Comm Bancorp. Moreover, Ray Gerald L & has 0.83% invested in Pfizer Inc. (NYSE:PFE) for 177,286 shares. Apriem Advsrs accumulated 205,017 shares. Pennsylvania-based Muhlenkamp & Incorporated has invested 0.35% in Pfizer Inc. (NYSE:PFE). Orbimed Advsrs Ltd Liability Corp invested in 5.17M shares or 2.14% of the stock. Fiduciary Com holds 567,334 shares or 0.6% of its portfolio. Quantum Mngmt holds 0.27% of its portfolio in Pfizer Inc. (NYSE:PFE) for 30,470 shares.

Btc Capital Management Inc decreased Broadcom Ltd stake by 2,740 shares to 13,216 valued at $2.34M in 2016Q4. It also reduced Thermo Fisher Scientific Inc (NYSE:TMO) stake by 4,021 shares and now owns 27,009 shares. Chevron Corp New (NYSE:CVX) was reduced too.

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada biopharmaceutical company. The company has market cap of $171.53 million. The Firm is engaged in development of new standards of care for individuals living with rare diseases. It currently has negative earnings. The Firm is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: